Quick Answer
Immunome Inc. reported Revenue (ASC 606) of $6.94 million for fiscal year 2025.
Immunome Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $6.94M | -23.2% |
| 2024 | $9.04M | -35.5% |
| 2023 | $14.02M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | -100.0% |
| June 30, 2025 | $4.01M | +69.8% | +37.2% |
| March 31, 2025 | $2.93M | +184.4% | +0.5% |
| September 30, 2024 | $2.91M | -18.4% | +23.1% |
| June 30, 2024 | $2.36M | -44.5% | +129.7% |
| March 31, 2024 | $1.03M | -56.5% | -71.1% |
| September 30, 2023 | $3.56M | — | -16.4% |
| June 30, 2023 | $4.26M | — | +80.3% |
- Immunome Inc. showed a decrease of -23.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, Immunome Inc.’s revenue (asc 606) has declined by 50.5% (from $14.02 million to $6.94 million).
- The most recent figure is from Immunome Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: